Blog Posts

Navneet Majhail: Congratulations to Stephen Strickland for presenting first-in-human results of SENTI-202

Stephen A. Strickland/sarahcannon.com

Apr 29, 2025, 09:16

Navneet Majhail: Congratulations to Stephen Strickland for presenting first-in-human results of SENTI-202

Navneet Majhail, Physician-in-Chief of Blood Cancers at the Sarah Cannon Transplant and Cellular Therapy Network, shared a post on LinkedIn:

“Congratulations to Stephen Strickland from Sarah Cannon Research Institute at TriStar Centennial Medical Center, Nashville for presenting first-in-human results of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy, in hematologic malignancies including AML at the AACR25 meeting.

Also appreciate the work from our investigators at Sarah Cannon Cancer Network Transplant and Cellular Therapy Programs in San Antonio (Dr Nosha Farhadfar) and Denver (Dr Ali Eghtedar) who are serving as co-authors on the abstract.”

More posts featuring Navneet Majhail.

AACR25 Ali Eghtedar AML cancer CAR-NK cell therapy CD33/FLT3 Denver fight against cancer Global fight against cancer Navneet Majhail Nosha Farhadfar OncoDaily Oncology San Antonio Sarah Cannon Research Institute Sarah Cannon Transplant and Cellular Therapy Network SENTI-202 Stephen Strickland TriStar Centennial Medical Center

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders